Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations.


Life Saving Drugs Program – Fabry disease – Medicines review summary

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Publication type:
General public

Help us improve

If you would like a response please use the enquiries form instead.